ARRY Key Stats
- Array BioPharma's CEO Presents at 2013 UBS Global Life Sciences Conference (Tran... May 21
- Array BioPharma's CEO Presents at Bank of America Merrill Lynch Healthcare Confe... May 16
- AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trials May 16
- Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company? May 16
- 10 ASCO '13 Abstracts You Can Read Right Now May 15
- Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Me... May 15
- 5 Biotechnology Stocks to Buy Now Investor Place May 15
- Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock May 15
- ARRAY BIOPHARMA INC Financials May 14
- Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? May 12
ARRY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Array BioPharma is up 60.66% over the last year vs S&P 500 Total Return up 28.49%, Celldex Therapeutics up 199.0%, and Cytokinetics up 26.67%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ARRY
Pro Report PDF for ARRY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ARRY Pro Report PDF
Pro Strategies Featuring ARRY
Did Array BioPharma make it into our Pro Portfolio Strategies?